Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.
Darlene Dobkowski, MA
Advertisement
Articles by Darlene Dobkowski, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5
